INVA - יחס חוב לטווח קצר להון עצמי inva.com

Innoviva, Inc. (INVA) business relies on stable payments for GSK respiratory drugs, ensuring high profitability during capital expansion. Growth is driven by the monetization of Entasis assets and active share buybacks. Current price action reflects the 0.00 indicator, while management focuses on optimizing intellectual property and identifying new profitable investment vehicles.

This ratio determines the share of short-term liabilities within the equity structure, allowing for an assessment of liquidity risk and the company's dependence on prompt debt refinancing. For Innoviva, Inc. (INVA), which accumulates royalties from GSK drug sales, this short-term financial leverage indicator confirms the business's ability to maintain its expansion strategy without the threat of default, balancing borrowing costs against return on assets.